Análisis Argos
LAD
LADCara
Lithia Motors, Inc. · Consumer Cyclical
US$ 358.31
precio al 2026-07-28
Valor justo Argos*
Sin estimar
vs. su valor justo
Sin estimar
Score Argos
41/100
LA RESPUESTA
El mercado le pide crezca 60% al año — más de lo que ha demostrado (5.5%). Estás pagando un futuro que todavía no probó: el margen de error es mínimo.
Recompensas
Sin recompensas destacadas.
Riesgos
!El precio pide más crecimiento del que la empresa ha demostrado.
!Balance frágil: la deuda pesa sobre el negocio.
VALOR1/6FUTURO3/6PASADO1/6SALUD1/6DIVIDENDO6/6
El Iris de calidad
VALOR1/6FUTURO3/6PASADO1/6SALUD1/6DIVIDENDO6/6
ValorCotiza por encima de su valor justo
FuturoCrecimiento moderado
PasadoHistorial débil
SaludBalance frágil
DividendoDevuelve capital al accionista
Score Argos41de 100Cara
Ingresos▲4%
US$ 37.6 B
Margen operativo▼14%
3.8%
Flujo de caja libre▼86%
US$ 0 B
Deuda neta
US$ 14.4 B
Lo esencial, sin ruido
Cap. de mercadoUS$ 8.2B
P/E10x
EV/EBITDA12.2x
FCF yield0.1%
ROIC5.1%
Margen operativo3.8%
Crecim. ingresos+4.0%/año
Piotroski F4/9
Competidores

Los rivales, con el mismo ojo

El Iris de calidad de cada competidor, lado a lado. Tocá uno para ver su análisis.

Novedades

Noticias recientes

zacks.com · 26 jun
Zacks Industry Outlook Lithia Motors, and Sonic
Lithia Motors, and Sonic have been highlighted in this Industry Outlook article.
zacks.com · 25 jun
2 Auto Retailers Worth Watching Despite Purchasing Power Erosion
U.S. auto retail faces volume pressure and eroding purchasing power. Yet LAD and SAH stand out with smart acquisitions, digital push and shareholder returns.
globenewswire.com · 9 jun
Lithia & Driveway (LAD) Rises to Number 123 on 2026 Fortune 500 List
MEDFORD, Ore., June 09, 2026 (GLOBE NEWSWIRE) -- Lithia & Driveway (NYSE: LAD) today announced that it ranked No.
globenewswire.com · 3 jun
JJP Biologics Announces Positive Interim Phase 1b Data for Nebaprubart (JJP-1212), an Anti-CD89 Antagonist, in Linear IgA Disease (LAD)
Warsaw, Poland – June 03, 2026 – JJP Biologics, ("JJPBio" or the "Company") a clinical-stage, immune-focused biotech that engineers precision antibodies to correct derailed immune pathways that drive autoimmune diseases and cancer, today announces positive interim data from its ongoing Phase 1b trial evaluating nebaprubart, also known as JJP-1212, its investigational potential first-in-class anti-CD89 antagonist, in patients diagnosed with Linear IgA Disease (LAD), a rare autoantibody-mediated skin disease.
zacks.com · 29 may
Why Is Lithia Motors (LAD) Up 1.9% Since Last Earnings Report?
Lithia Motors (LAD) reported earnings 30 days ago. What's next for the stock?
globenewswire.com · 26 may
Lithia & Driveway (LAD) Announces Share Repurchase Authorization Increase
MEDFORD, Ore., May 26, 2026 (GLOBE NEWSWIRE) -- Lithia & Driveway (NYSE: LAD) announced today an increase to its share repurchase authorization of $500 million to bring the current remaining authorization to $726 million.
investorplace.com · 11 may
The One Market Edge Wall Street Can’t Steal From You
Small-cap stocks may lead after Fed rate cuts, giving individual investors an edge Wall Street is too big to use.
seekingalpha.com · 29 abr
Lithia Motors, Inc. (LAD) Q1 2026 Earnings Call Transcript
Lithia Motors, Inc. (LAD) Q1 2026 Earnings Call Transcript

* Valor justo Argos: estimación educativa del valor intrínseco según el propio flujo de caja de la empresa y su capacidad de crecimiento — no un precio objetivo ni una recomendación. Esto es información y educación, no asesoría de inversión. Rendimiento pasado no garantiza resultados futuros.